Antibody-based therapy of non-Hodgkin's lymphoma

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 3, 2002, Pages 449-465

  Foran, James M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; Antibody dependent cellular cytotoxicity; Chimeric; Complement dependent cytotoxicity; Complementarity determining region; I131 tositumomab; Ibritumomab tiuxetan; Monoclonal antibody; Radioimmunotherapy; Rituximab

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; APOLIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE PHOSPHATE; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; IMMUNOTOXIN BL22; INDIUM 111; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90; CD20 ANTIBODY; CD22 ANTIGEN; CD52 ANTIGEN; FLUDARABINE; INTERLEUKIN 2 RECEPTOR ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY;

B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG SYNTHESIS; DRUG USE; FEVER; FOLLICULAR LYMPHOMA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPOTENSION; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MYCOSIS FUNGOIDES; MYELODYSPLASIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; REVIEW; RIGOR; T CELL LEUKEMIA; THROMBOCYTOPENIA; UNITED STATES; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CELL CYCLE; CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DEVELOPMENT; HEMATOLOGIC DISEASE; LARGE CELL LYMPHOMA; RADIOIMMUNOTHERAPY; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, NON-HODGKIN; TREATMENT OUTCOME;

EID: 0036459266     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0222     Document Type: Article

References (86)

1. Ehrlich P. On immunity with special reference to cell life. Proceedings of the Royal Society of London (Biology) 1900; 66: 424-448.
2. Laszlo J, Buckley CE III & Amos DB. Infusion of isologous immune plasma in chronic lymphocytic leukemia. Blood 1968; 31: 104-110.
3. Currie GA. Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. British Journal of Cancer 1972; 26: 141-153.
4. Köhler G & Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
5. Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Research 1980; 40: 147-154.
6. Miller RA, Maloney DG, Warnke R & Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New England Journal of Medicine 1982; 306: 517-522.
7. Meeker T, Lowder J, Clearly ML et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. New England Journal of Medicine 1985; 312: 1658-1665.
8. Grossbard ML, Press OW, Appelbaum FR et al. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863-878.
9. Riechmann L, Clark M, Waldmann H & Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
10. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
11. Stashenko P, Nadler LM, Hardy R & Schlossman SF. Characterization of a human B lymphocyte-specific antigen. Journal of Immunology 1980; 125: 1678-1685.
12. Press OW, Farr AG, Borroz KI et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Research 1989; 49: 4906-4912.
13. Tedder TF & Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today 1994; 15: 450-454.
14. Vose JM, Giles FJ, Manshouri T et al. High levels of soluble CD20(sCD20) in patients with non-Hodgkin's lymphoma (NHL): correlation with clinical behavior and contrast with patients with Hodgkin's disease (HD). Blood 2001; 98 (supplement 1): 767a.
15. Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584-591.
16. Harjunpää A, Junnikkala S & Meri S. Rituximab (Anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology 2000; 51: 634-641.
17. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
18. Weng W-K & Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumour cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin's lymphoma. Blood 2001; 98: 1352-1357.
19. Treon SP, Emmanouilides CE, Kimby E et al. Extended rituximab therapy is highly active and facilitates hematological recovery in patients with lymphoplasmacytic lympohoma (Waldenströms macroglobulinemia). Proceedings of ASCO 2002; 21: 268a.
20. Flieger D, Renoth S, Beier I et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cellular Immunology 2000; 204: 55-63.
21. Voso MT, Pantel G, Rutella S et al. Effector cell-mediated mechanisms play the dominant role in the cytotoxicity of rituximab on human peripheral blood B-cells from normal donors and patients with CLL. Blood 2000; 96 (supplement 1): 338a.
22. van der Kolk LE, de Haas M, Grillo-Lopez AJ et al. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002; 16: 693-699.
23. Clynes RA, Towers TL, Presta LG & Ravetch JV. Inhibitory Fc: receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine 2000; 4: 443-446.
24. Fitzgibbon J, Hill AS, Arch RS et al. Identification of a novel polymorphism in the human FCGR2B gene: correlation with response to rituximab treatment in patients with follicular lymphoma. Blood 2000; 96 (supplement I): 179b.
25. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc: receptor FcγRIIIa gene. Blood 2002; 99: 754-758.
26. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology 2000; 18: 317-324.
27. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell lymphocytic leukemia. Blood 2001; 98: 1326-1331.
28. Golay J, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389.
29. Ansell SM, Witzig TE, Kurtin PJ et al. Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002; 99: 67-74.
30. Foran JM, Norton AJ, Micallef INM et al. Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis. British Journal of Haematology 2001; 114: 881-883.
31. Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038-1043.
32. Shan D, Ledbetter JA & Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology and Immunotherapy 2000; 48: 673-683.
33. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2138) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
34. Maloney DG, Grillo-Lopez AJ, Bodkin D et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology 1997; 15: 3266-3274.
35. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2BB (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
36. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998; 16: 2825-2833.
37. Foran JM, Gupta RK, Cunningham D et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology 2000; 109: 81-88.
38. Grillo-Lopez AJ, Hedrick E, Rashford M & Benyunes; M. Rituximab: ongoing and future clinical development. Seminars in Ontology 2002; 29(1 supplement 2): 105-112.
39. Hainsworth JD, Burrism HA, Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052-3056.
40. Ghielmini M, Hsu Schmitz S-F, Cogliatti SB et al. Maintenance treatment with 2-monthly rituximab after standard weekly x 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Annals of Oncology 2002; 13 (supplement 2): 38a.
41. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
42. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862.
43. Byrd JC, White CA, Link B et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Annals of Oncology 1999; 10: 1525-1527.
44. Treon SP, Agus DB, Link B et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotheropy 2001; 24: 272-279.
45. Dimopoulos MA, Zervas C, Zomas A et al. Treatment of Waldenströms macroglobulinemia with rituximab. Journal of Clinical Oncology 2002; 9: 2327-2333.
46. Conconi A, Thieblemont C, Martinelli G et al. IELSG phase II study of rituximab in MALT lymphoma: final results. Proceedings of ASCO 2002; abstract 1067, 267a.
47. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology 2000; 18: 3135-3143.
48. Davis TA, White CA, Grillo Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. Journal of Clinical Oncology 1999; 17: 1851-1857.
49. Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 1999; 94: 2217-2224.
50. Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology 1999; 17: 791-795.
51. Kunzmann V, Ruediger T, Hallek M et al. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 2001; 98: 1991-1992.
52. Piro LD, White CA, Grillo-Lopez AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology 1999; 10. 655-661.
53. Avilés A, León I, Díaz-Maqueo JC et al. Rituximab in the treatment of refractory follicular lymphoma - six doses are better than four. Journal of Hematotherapy and Stem Cell Research 2001; 10: 313-316.
54. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology 2001; 19: 2153-2164.
55. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology 2001; 19: 2165-2170.
56. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy & Radiopharmacology 1997; 12: 177-186.
57. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology 1999; 17: 268-276.
58. Czuczman MS, Grillo-Lopez A, White CA et al. Progression free survival after six years median follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy. Blood 2001; 98 (supplement 1): 601a.
59. Czuczman MS, Fallon A, Mohr A et al. Phase II study of rituximab plus fludarabine in patients (pts) with low-grade lymphoma (LGL): final report. Blood 2001; 98 (supplement 1): 601a.
60. Byrd JC, Peterson BL, Park K et al. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: results from CALGB 9712. Blood 2001; 98 (supplement 1): 772a.
61. Sarris AH, Jiang Y & Tsimberidou AM. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Seminars in Oncology 2002; 29 (supplement 2): 48-55.
62. McLaughlin P, Hagemeister FB, Rodriguez MA et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Seminars in Oncology 2000; 27: 37-41.
63. Wierda W, O'Brien S, Albitar M et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001; 98 (supplement 1): 771a.
64. Magni M, DiNicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96 864-869.
65. Brugger W, Hirsch J, Repp R et al. Multicenter phase II study with rituximab treatment for follicular and mantle cell lymphoma after high-dose therapy and autologous blood stem cell transplantation. Annals of Oncology 2002; 13 (supplement 2): 38a.
66. Foran JM, Cunningham D, Coiffier B et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Annals of Oncology 2000; 11 (supplement 1): S117-S121.
67. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology 2002; 20: 1288-1294.
68. Romaguera J, Cabanillas A, Dang N et al. Mantle cell lymphoma (MCL) - high rates of complete remission (CR) and prolonged failure-free survival (FFS) with rituxan-hyperCVAD (R-HCVAD) without stem cell transplant (SCT). Blood 2001; 98 (supplement 1): 726a.
69. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
70. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 2001; 19: 389-397.
71. Coiffier B, Lepage E, Briére J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New England Journal of Medicine 2002; 346: 235-242.
72. Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-IH Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 1997; 15: 1567-1574.
73. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath- IH) in patients who have failed fludarabine: results of a large international study. Brood 2002; 99: 3554-3561.
74. Kennedy B, Rawstron A, Carter C et al. Campath-IH and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-2247.
75. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-IH monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-IH Treatment in Low-Grade Non-Hodgkin's lymphoma. Journal of Clinical Oncology 1998; 16: 3257-3263.
76. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-IH. Blood 2001; 98. 1721-1726.
77. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-IH prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
78. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-IH in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
79. Leonard JP, Coleman M, Schuster MW et al. Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results. Blood 1999; 94 (supplement 1): 92a.
80. Leonard JP, Coleman M, Matthews JC et al. High complete response rate following epratuzumab (anti-CD22) and rituximab (anti-CD20) combination antibody therapy in follicular non-Hodgkin's lymphoma. Annals of Oncology 2002; 13 (supplement 2): 38a.
81. Link BK, Kahl B, Czuczman M et al. A phase II study of Remitogen™ (HuID10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic or marginal zone/MALT B-cell lymphoma. Blood 2001; 98 (supplement 1): 606a.
82. Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. New England Journal of Medicine 2001; 345: 241-247.
83. Kaminski MS, Zasadny KR, Francis IR et al. Radioimmunotherapy of B-cell lymphoma with [11311]anti-B1 (anti-CD20) antibody. New England Journal of Medicine 1993; 329: 459-465.
84. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine 1 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 2001; 19: 3918-3928.
85. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
86. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 2002; 20: 2453-2463.